Peregrine to Present at Stifel Nicolaus Healthcare Conference September 8, 2011 at 11:30 AM EDT
(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 09/01/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 2011 Stifel Nicolaus Healthcare Conference in Boston, Massachusetts on Thursday, September 8, 2011 at 11:30 AM EDT.
Peregrine's presentation will be webcast live and available for replay until September 22, 2011 at:
For more information about this conference, please visit:
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at .
Contact:
Amy Figueroa or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.09.2011 - 06:00 Uhr
Sprache: Deutsch
News-ID 1036057
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TUSTIN, CA
Phone:
Kategorie:
Trials
Anmerkungen:
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peregrine to Present at Stifel Nicolaus Healthcare Conference September 8, 2011 at 11:30 AM EDT
"
steht unter der journalistisch-redaktionellen Verantwortung von
Peregrine Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
